| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Sriram Subramaniam | Q56910323 |
| P2093 | author name string | Israel Steiner | |
| P2860 | cites work | Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis | Q40703702 |
| Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system | Q40796002 | ||
| The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study | Q43589373 | ||
| Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes | Q44021545 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 939-45 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis | |
| P478 | volume | 58 |
| Q40567848 | A mouse model for testing remyelinating therapies |
| Q48175463 | Active induction of experimental allergic encephalomyelitis |
| Q38513547 | Acute disseminated encephalomyelitis: current knowledge and open questions |
| Q37169940 | Analysis of nociception, sex and peripheral nerve innervation in the TMEV animal model of multiple sclerosis. |
| Q38396248 | Animal models of Multiple Sclerosis. |
| Q37766015 | Animal models of multiple sclerosis--potentials and limitations |
| Q36492301 | Antioxidants in multiple sclerosis: do they have a role in therapy? |
| Q36299698 | Apoptosis of oligodendrocytes in the central nervous system results in rapid focal demyelination |
| Q38056688 | Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis |
| Q37891882 | Autoimmunity and inflammation: murine models and translational studies |
| Q38653397 | Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology |
| Q57041869 | B-cell subsets: cellular interactions and relevance in multiple sclerosis |
| Q48366273 | Blood-brain barrier alterations in the cerebral cortex in experimental autoimmune encephalomyelitis |
| Q90638165 | CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis |
| Q36956709 | Cellular approaches for stimulating CNS remyelination |
| Q34220882 | Chronic immobilisation stress ameliorates clinical score and neuroinflammation in a MOG-induced EAE in Dark Agouti rats: mechanisms implicated. |
| Q37428522 | Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). |
| Q37849455 | Critical appraisal of animal models of multiple sclerosis |
| Q22252578 | Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy |
| Q36827362 | Current concepts of the cellular and molecular pathophysiology of multiple sclerosis |
| Q57521580 | Current developments in MRI for assessing rodent models of multiple sclerosis |
| Q41762734 | Deep gray matter T2 hypointensity correlates with disability in a murine model of MS. |
| Q35491908 | Defective structural RNA processing in relapsing-remitting multiple sclerosis |
| Q38186202 | Demyelination in multiple sclerosis |
| Q37690014 | Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis |
| Q37243842 | Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design |
| Q35589934 | Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). |
| Q46255661 | Experimental autoimmune encephalomyelitis from a tissue energy perspective. |
| Q37614318 | Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development |
| Q89942990 | Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis |
| Q36662903 | Glatiramer acetate therapy for multiple sclerosis: a review. |
| Q35758697 | Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation |
| Q37855723 | Immunologic aspects of multiple sclerosis |
| Q36785951 | Immunopathogenesis of multiple sclerosis: concepts and controversies |
| Q37467994 | Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human primate species |
| Q38186205 | Infections and multiple sclerosis |
| Q80304452 | Infectious causes of multiple sclerosis |
| Q34734088 | Inhibition of autoimmune Chagas-like heart disease by bone marrow transplantation |
| Q27496011 | Is Multiple Sclerosis an Autoimmune Disease? |
| Q42341307 | Is there a place for 'immuno' in the immunotherapy of multiple sclerosis? |
| Q34475822 | MS14 down-regulates lipocalin2 expression in spinal cord tissue in an animal model of multiple sclerosis in female C57BL/6. |
| Q35197096 | Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders |
| Q91210808 | Multiple sclerosis and cognition: synaptic failure and network dysfunction |
| Q35683398 | Multiple sclerosis: myeloperoxidase immunoradiology improves detection of acute and chronic disease in experimental model. |
| Q38330408 | Nanomaterial applications in multiple sclerosis inflamed brain |
| Q38863014 | Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats |
| Q37854824 | Of mice and men: experimental autoimmune encephalitis and multiple sclerosis. |
| Q38609231 | Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis |
| Q57374579 | Partitioning of myelin basic protein into membrane microdomains in a spontaneously demyelinating mouse model for multiple sclerosisThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB — Membrane Proteins in He |
| Q80285957 | Passive induction of experimental allergic encephalomyelitis |
| Q36904407 | Pathoetiology of multiple sclerosis: are we barking up the wrong tree? |
| Q36990484 | Peptidylarginine deiminase 2 (PAD2) overexpression in transgenic mice leads to myelin loss in the central nervous system |
| Q34139149 | Post infectious CNS disorders: towards a unified approach. |
| Q34372998 | Preclinical (1)H-MRS neurochemical profiling in neurological and psychiatric disorders |
| Q82270960 | Quo vadis multiple sclerosis? |
| Q85981161 | Reducing suffering in experimental autoimmune encephalomyelitis (EAE) |
| Q34155080 | Reimagining Alzheimer's disease--an age-based hypothesis |
| Q38257152 | Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches |
| Q28290823 | Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study |
| Q90747724 | Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution? |
| Q92000490 | Respiratory virus-induced heterologous immunity: Part of the problem or part of the solution? |
| Q88615583 | Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery |
| Q35070143 | Secreted phospholipase A2 activity in experimental autoimmune encephalomyelitis and multiple sclerosis |
| Q37539049 | Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis. |
| Q41835825 | Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue? |
| Q36474316 | The B cell response in multiple sclerosis |
| Q38115525 | The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis |
| Q36110218 | The conundrum of iron in multiple sclerosis--time for an individualised approach |
| Q38059361 | The development of myelin repair agents for treatment of multiple sclerosis: progress and challenges. |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q38186206 | The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. |
| Q33960847 | The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis |
| Q34442604 | The impact of microglial activation on blood-brain barrier in brain diseases. |
| Q36961600 | The origin and application of experimental autoimmune encephalomyelitis |
| Q37380834 | The relevance of animal models in multiple sclerosis research |
| Q38111421 | The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment. |
| Q34075874 | The role of infections in the pathogenesis and course of multiple sclerosis |
| Q39295050 | The role of regulatory T cells in nervous system pathologies |
| Q37782118 | Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain–Barré syndrome? |
| Q37772026 | Translational research in neurology and neuroscience 2010: multiple sclerosis |
| Q42442587 | UV radiation, vitamin D, and multiple sclerosis |
| Q35374873 | Varicella zoster virus and relapsing remitting multiple sclerosis |
| Q38064230 | Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virus. |
| Q38020092 | Will the real multiple sclerosis please stand up? |
Search more.